Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Breast Cancer Clinical Trial

— RIBBIT  

Official title:

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03462251
• Other study ID #: IOM-050371
• Status: Completed
• Phase: Phase 3
• Start date: May 24, 2018
• Est. completion date: November 30, 2022

Study information

• Verified date: January 2023
• Source: iOMEDICO AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of first-line treatment ribociclib in combination with aromatase inhibitor (AI) or fulvestrant OR capecitabine with bevacizumab OR paclitaxel with / without bevacizumab in patients with HR-positive, HER2-negative advanced breast cancer with visceral metastasis. Half of the patients will receive a combination of ribociclib and AI/fulvestrant while the other half will receive capecitabine + bevacizumab or paclitaxel +/- bevacizumab.

Description:

This is a prospective, randomized, open-label, two-arm, multicenter, interventional phase III trial in Germany. The study will include adult women with HR-positive, HER2-negative advanced breast cancer with visceral metastases, who received no prior therapy for advanced disease. 158 patients will be enrolled and randomized 1:1 (stratified by the presence of lung and / or liver metastases) to receive Arm A: a combination of ribociclib and AI or fulvestrant; OR Arm B: capecitabine + bevacizumab OR paclitaxel +/- bevacizumab Treatment will be continued until disease progression, intolerable toxicity or death. Progression-free survival (PFS) will be based on tumor assessments by local radiologists/investigator using RECIST v1.1 criteria. Treatment might be continued beyond RECIST-defined progressive disease (PD) in case of negligible or clinically irrelevant disease progression according to the investigator's discretion until clinically relevant disease progression or symptomatic deterioration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years.
• Any menopausal status. If pre-/perimenopausal, agreement to receive LHRH agonist (goserelin or leuprorelin) / ovarian ablation in case of randomization to arm A
• Locally confirmed diagnosis of metastatic adenocarcinoma of the breast without prior systemic antineoplastic therapy in the palliative setting.
• Hormone receptor (HR)-positive disease, defined as estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive.
• Human epidermal growth factor receptor 2 (HER2)-negative disease (defined as immunohistochemistry (IHC) status HER2 negative/+ or IHC HER2++ with chromosomal in situ hybridization (CISH)/fluorescent in situ hybridization (FISH) negative).
• Presence of visceral metastases (additional non-visceral metastases are allowed).
• Presence of target and / or non-target lesions according to RECIST v1.1
• Patients eligible for palliative treatment with AI / fulvestrant + ribociclib and capecitabine + bevacizumab or paclitaxel + / - bevacizumab according to the respective SmPCs.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Adequate organ and bone marrow function within 7 days prior to randomization.
• Standard 12-lead ECG values: QT Interval Corrected by the Fridericia Correction Formula (QTcF) interval at screening < 450 msec; Mean resting heart rate 50-90 bpm (determined from the ECG)
• Signed written informed consent prior to beginning of protocol-specific procedures.

Exclusion Criteria:

• Any prior systemic palliative therapy
• Prior treatment with any cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
• Prior adjuvant or neoadjuvant taxane therapy if last application within 12 months prior to entering the study.
• Patient is concurrently using other anti-cancer therapy.
• Patient has had major surgery within 28 days prior to randomization or has not recovered from major side effects or wound is not fully recovered.
• Patient has received extended-field radiotherapy = 4 weeks or limited-field radiotherapy = 2 weeks prior to randomization.
• Known hypersensitivity to ribociclib, AI, paclitaxel, bevacizumab or any of their excipients, or against peanut, soya, Chinese hamster ovarian cell products or macrogolglycerol ricinoleate-35.
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality (e.g. history of myocardial infarction within 6 months prior study entry, long QT syndrome, clinically significant cardiac arrhythmias or systolic blood pressure > 140 or < 90 mmHg or diastolic blood pressure > 90 mmHg).
• Patient has history of arterial thrombosis within 12 months prior to entering the study.
• Patient has proteinuria (= 2+ on urine dipstick)
• Patient with congenital bleeding diathesis, acquired coagulopathy or under full dose of anticoagulants.
• Patient is currently receiving strong inducers or inhibitors of CYP3A4/5 or medication with narrow therapeutic window that are predominantly metabolized through CYP3A4/5 and cannot be discontinued 7 days prior to start of study treatment.
• Known presence of cerebral metastases unless at least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment and clinically stable central nervous system tumor at the time of screening.
• Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.
• Patient is currently receiving or has received systemic corticosteroids or other chronic immunosuppressive therapy = 2 weeks prior to starting study drug.
• Patients with advanced symptomatic, visceral spread, that are at risk of lifethreatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement).
• Patient has a known history of HIV infection (testing not mandatory).
• Patient has active untreated or uncontrolled fungal, bacterial or viral infection.
• Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, etc.).
• Participation in prior investigational studies within 30 days prior to randomization or within 5-half lives of the investigational product, whichever is longer.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• HER 2 Negative Breast Cancer
• Hormone Receptor Positive Tumor

Intervention

Combination Product:
• Ribociclib and aromatase inhibitor or fulvestrant
Combination of ribociclib and aromatase inhibitor or fulvestrant
• Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab

Locations

Country	Name	City	State
Germany	Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin	Aachen
Germany	Klinikum Mittelbaden Baden-Baden Balg	Baden-Baden
Germany	Gynäkologisches Zentrum Bonn	Bonn
Germany	St.-Johannes-Hospital Gynäkologie und Geburtshilfe	Dortmund
Germany	BAG / Onkologische Gemeinschaftspraxis	Dresden
Germany	Universitätsklinikum Essen	Essen
Germany	Praxis für interdisziplinäre Onkologie & Hämatologie	Freiburg
Germany	Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz	Goslar
Germany	Gemeinschaftspraxis für Innere Medizin, Hämatologie, Onkologie, Gastroenterologie	Halle
Germany	OncoResearch Lerchenfeld GmbH	Hamburg
Germany	Onkologische Schwerpunktpraxis	Heidelberg
Germany	IDGGQ GbR	Kaiserslautern
Germany	Hämato-Onkologisches Zentrum Kassel MVZ GmbH	Kassel
Germany	Praxis Dr. med. Bettina Peuser	Leipzig
Germany	Gemeinschaftspraxis für Hämatologie und Onkologie	Mühlheim
Germany	Hämatologisch-onkologische Gemeinschaftspraxis	Münster
Germany	Praxis Dr. med. Jens Uhlig	Naunhof
Germany	Klinikum Neumarkt	Neumarkt
Germany	Onkologie Offenburg	Offenburg
Germany	Gemeinschaftspraxis für Hämatologie und Onkologie	Ravensburg	Baden-Wuerttemberg
Germany	Praxis und Tagesklinik für Onkologie und Hämatologie	Recklinghausen
Germany	Tumorzentrum und Hausarztpraxis Rötha Leipziger-Land	Rötha
Germany	Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie	Singen
Germany	Onkologische Schwerpunktpraxis	Speyer
Germany	g.SUND Gynäkologie Kompetenzzentrum Stralsund	Stralsund
Germany	Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH	Villingen-Schwenningen
Germany	Gemeinschaftspraxis für Hämatologie und Onkologie	Westerstede

Sponsors (2)

Lead Sponsor	Collaborator
iOMEDICO AG	Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Symptomatic PFS (sPFS)	sPFS is defined as time from randomization until symptomatic deterioration (new or worsening of persisting symptoms) or death as per local investigator.	Up to approximately 15 months.
Primary	Efficacy in terms of PFS	PFS is defined as time from randomization to progression of disease or death of any cause, whichever comes first. It will be assessed by imaging until progressive disease or start of next-line therapy.	Up to approximately 15 months.
Secondary	Overall Survival (OS)	OS is defined as time from randomization to death of any cause.	Up to approximately 48 months.
Secondary	Overall Response Rate (ORR)	ORR is defined as the proportion of patients with best overall response of complete or partial response according to RECIST 1.1.	Up to approximately 15 months.
Secondary	Clinical Benefit Rate (CBR)	CBR is defined as the proportion of patients with best overall response of complete or partial response or stable disease lasting 24 weeks or more according to RECIST 1.1.	Up to approximately 15 months
Secondary	Time To Response (TTR)	TTR is defined as time from randomization to first occurrence of any response (complete or partial) according to RECIST 1.1.	Up to approximately 15 months.
Secondary	Number of participants with Adverse Events	Type, frequency and severity (according to CTCAE v4.03) of adverse events	Until 30 days after end of treatment, up to approximately 16 months.
Secondary	Time to deterioration of ECOG performance status	Time to deterioration of ECOG performance status by at least one point from baseline.	Until 30 days after end of treatment, up to approximately 16 months
Secondary	Tolerability of treatment	By-patient listings of safety laboratory (hemoglobin, platelets, white blood cells with differentials, international normalized ratio , serum creatinine, bilirubin, Alanine-Aminotransferase (ALT) and Aspartate-Aminotransferase (AST)).	Until 30 days after end of treatment, up to approximately 16 months.
Secondary	corrected QT interval (QTc) time	By-patient listings of cardiac monitoring.	Until 30 days after end of treatment, up to approximately 16 months.
Secondary	Health-related quality of life (QoL)	Health-related QoL will be assessed with the EORTC Quality of life questionnaire (QLQ) QLQ-C30.	Up to 36 months.
Secondary	Side effects of treatment	One question on treatment burden	Up to 36 months.
Secondary	Time spent on treatment	Burden by treatment will be assessed with 4 questions on time spent on treatment	Up to 36 months